A novel approach to assess the prognostic value of toxicity profiles in gastric cancer patients undergoing preoperative treatment

Genitourinary Cancer

A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer

Eur Urol

Ghodoussipour S, Bivalacqua T, Bryan RT, Li R, Mir MC, Palou J, Psutka SP, Sundi D, Tyson MD, Inman BA

doi: 10.1016/j.eururo.2025.02.010

SPECIAL REPORT

Breast Cancer

Managing Side Effects in Breast Cancer Treatment

Gastrointestinal Cancer

Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis

Cancer Treat Rev

Holz A, Paul B, Zapf A, Pantel K, Joosse SA

doi: 10.1016/j.ctrv.2025.102999

SPECIAL REPORT

Breast Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Gastrointestinal Cancer

Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study

Int J Cancer

Slotman E, Pape M, van Laarhoven HWM, Pouw RE, van der Linden YM, Verhoeven RHA, Siesling S, Fransen HP, Raijmakers NJH

doi: 10.1002/ijc.35314

SABCS 2024

Breast Cancer

Advancing Breast Cancer Treatment with Elacestrant

Breast Cancer

Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial

Eur J Cancer

Livraghi L, Martella F, Ghilli M, Angiolini C, Magnanini S, Moretti E, Bengala C, Risi E, Molinara E, Pazzagli I, Malorni L, Donati S, Gabellini S, Martignetti A, Giannessi P, Sanna G, Barellini L, Biagioni C, Boni L, Bianchi S, Roncella M, Biganzoli L

doi: 10.1016/j.ejca.2024.115108

Lung, Respiratory and Thoracic Cancer

Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer

J Thorac Oncol

Heersche N, Lanser DAC, Muntinghe-Wagenaar MB, Mohmaed Ali MI, Ulas EB, Trooster TMA, de Jonge E, Oomen-de Hoop E, Paats MS, Bahce I, Croes S, Hendriks LEL, van der Wekken AJ, Dingemans AC, Huitema ADR, van Schaik RHN, Mathijssen RHJ, Veerman GDM

doi: 10.1016/j.jtho.2024.11.025

Gastrointestinal Cancer

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database

J Clin Oncol

Bachet JB, de Gramont A, Raeisi M, Rakez M, Goldberg RM, Tebbutt NC, Van Cutsem E, Haller DG, Hecht JR, Mayer RJ, Lichtman SM, Benson AB, Sobrero AF, Tabernero J, Adams R, Zalcberg JR, Grothey A, Yoshino T, André T, Shi Q, Chibaudel B

doi: 10.1200/JCO-24-01968

Related content

A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer

Managing Side Effects in Breast Cancer Treatment

Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study

Advancing Breast Cancer Treatment with Elacestrant

Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial

Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database